TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Satisfaction Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change From Baseline in Serum Alkaline Phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in coma recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cognitive functioning level
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vascular Nitric oxide bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prevalence of right ventricle dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Usual pain intensity in lower extremity(ies)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score of Fraboni's Scale for Ageism
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in benevolent subscores of the Ambivalent ageism scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in hostile subscores of the Ambivalent ageism scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Core acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcome of women with cervical cancer
Endpoint domain: Mortality/survival
Primary endpoint: Total Plasmalogen Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone-free lean body mass improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-sec chair stand test improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength of hand grip improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Expiratory Flow Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Checkpoint inhibitor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Preeclampsia Diagnosis With Severe Features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to improvement of NYHA class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diuretic efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV testing uptake at point of test offer in men
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV treatment linkage at 1 year in men
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Population-level HIV-related mortality in men
Endpoint domain: Mortality/survival
Primary endpoint: Change in Colorectal Cancer Screening Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concentration of curcumin in colorectal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Count of Participants With Elevated ALT at Baseline and With Clinically Significant Improvement at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Count of Participants With Elevated GGT at Baseline and With Clinically Significant Improvement at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Count of Participants With Abnormal MRCP Imaging at Baseline and With Clinically Significant Improvement at Year 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Enrollment (Young Adult Survivors)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Retention in Study (Young Adult Survivors)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completion of the Intervention (Young Adult Survivors)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes of serum lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient view of the prescription (LRx) and consultation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Healthcare Practitioner (HCP) view of the prescription (LRx) and consultation
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Occlusal load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brain amyloid load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Root-mean-square Deviation of Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Root-mean-square Deviation of Respiratory Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Pain Level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change of Perceived Stress Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of participants with sustained virologic response 12 weeks (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events leading to permanent discontinuation of study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Number of T1 Gadolinium-Enhancing Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of participants with treatment-related adverse events concerning ECG
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment-related adverse events concerning safety laboratory
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment-related adverse events concerning vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment-related adverse events concerning clinical observations
Endpoint domain: Adverse events/effects
Primary endpoint: Change in apelin mediated forearm blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Kunming Locomotor Scale (KLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drinking outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Voice Handicap Index (VHI) overall score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Systolic pressure variation (SPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence of cleft lip and palate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global score of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Watcha behavior scale for emergence agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in arterial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite incidence of death, non-fatal reinfarction and stroke
Endpoint domain: Mortality/survival
Primary endpoint: Plasma ABP-671 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in IMR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variation in absolute coronary flow values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in brain NAD+ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients included for intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: sensitivity and specificity of questions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Establishment of paresthesia threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Establishment of motor threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acute Adverse Pain Responses using short-form McGill Pain Questionnaire
Endpoint domain: Adverse events/effects
Primary endpoint: Acute Adverse Pain Responses using long form Brief pain inventory (BPI)
Endpoint domain: Adverse events/effects
Primary endpoint: SKAMP-Combined Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative degrees of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in arterial stiffness (cf-PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence rate of hemorrhage related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Bronchoconstriction response to methacholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Suicidal Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects by Frailty Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Quality as Assessed by Polysomnographic Recorded (PSG) Parameters
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sleep Efficiency (PSG SE)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Awakenings (PSG NAW)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Virological failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EEG Power in Alpha, Slow, and Delta Bands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: TMA Event-free Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematologic Normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete TMA Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impulse value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact time of each gait phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cormack-Lehane Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ASAS 20 responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indicators per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of local/regional control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of systemic disease control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of radiotherapy administered concurrently with etoposide and cisplatin chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composite time spent in ideal potassium range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in METAVIR score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Uptake of 18F-PSMA PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Latency to Persistent Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of device related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of myocardial perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anal fistula recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Foot bone mineral density (f-BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient rated tennis elbow evaluation (PRTEE)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensitivity in detecting active DMO/PDR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combination of cardiac death, non-fatal myocardial infarction, and symptom-driven revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients comprehensively screened
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of denufosol
Endpoint domain: Adverse events/effects
Primary endpoint: Utility of denufosol in treating uveitis associated macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bullying Cognitions Scale for Children mean scores (BCSC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Empathy Scale for Children and Adolescents (ESCA)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of Predicting pCR (Pathologic Complete Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of Predicting pCR (Pathologic Complete Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic Accuracy of Contrast-enhanced Mammography in Assessing pCR or Non Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Constant Murley Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Oxford Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rates of resident communication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total medical errors
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Dose-Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Treatment-Emergent Adverse Events (TEAE), Treatment-Emergent Serious Adverse Events (TESAE) With a CTCAE Grade of 3 or 4
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Serum Biochemistry (Albumin, Protein, Hemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MMT retention rate
Endpoint domain: Mortality/survival
Primary endpoint: Illicit opioid use rate
Endpoint domain: Adverse events/effects
Primary endpoint: Entry into Intensive Care with invasive mechanical ventilation or death from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Incidence Rate of Acute Serious Bacterial Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Average Number of Daily Moderate to Severe Hot Flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opsonophagocytic antibody activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: recidivism
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in 24-h ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Facial contour restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seated Automated Office Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage change of bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in IIEF-5 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Requirement of vasopressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerability of curcumin
Endpoint domain: Adverse events/effects
Primary endpoint: Tear histamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obstructive sleep apnea parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in volumes and areas of upper airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sympathetic hyperactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjectively-rated pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the percentage of immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of postoperative phlebitis
Endpoint domain: Adverse events/effects
Primary endpoint: Extracellular Volume (ECV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of Related/Not Related Local and/or Systemic Reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Vascular vasomotor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Participation to the colonoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severity of indigestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of indigestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Count of Participants Who Self-reported Adequate Relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Death from cardiac cause
Endpoint domain: Mortality/survival
Primary endpoint: oocyte survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Length of hospital stay until fit-for-discharge criteria are reached
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Diagnostic accuracy of serum creatinine changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incrustation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary pH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Self-control below values 6.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Change From Baseline in Anti-fXa Activity at the Nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CAPS-5 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of liver fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Millimeter difference in position between planned and actual target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sICH
Endpoint domain: Adverse events/effects
Primary endpoint: Physiological Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of active cybersexuality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anxiety Disorders Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Achieving HBV DNA ≤300 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability of GT0918
Endpoint domain: Adverse events/effects
Primary endpoint: Blood lead concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total 10 year cardiovascular disease (CVD) risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetics of total radioactivity in plasma and whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mass balance of [14C]-AMG 706 in urine and faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucose lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in arterial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Candidate biomarkers of risk or of early diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in urinary protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent of Patient's Headaches With Pain Relief at 2 Hours After the Initial Dose of Test Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Response According to RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression-free Survival According to RECIST
Endpoint domain: Mortality/survival
Primary endpoint: Bone density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Soreness Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: commitment to abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quit attempts
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: medical-economic impact
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HIV-1 Infection Rate
Endpoint domain: Mortality/survival
Primary endpoint: HIV-1 Viral Load Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in antihypertensive dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes